Dianthus Therapeutics Stock (NASDAQ: DNTH)

Dianthus Therapeutics

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

DNTH

DXYZ

FLIC

POWL

QDEL

Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

ULTA, Ulta Beauty

EOSE

ESTC

HSHP

ULTA

Ulta Beauty Reports Downbeat Results, Joins Elastic And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Penny Stocks

Small Cap

Intraday Update

ABTS

ALAB

AMTX

ANNX

ATER

BACK

BCAN

BIOL

BNAI

BTDR

CUTR

CZOO

EGOX

FRSX

GRDI

GRFS

GTBP

ISPR

JOAN

LAAC

LICY

LULU

LXEH

MRNO

NKTX

NVFY

OCGN

OTLK

RETO

SINT

SLNA

SMLP

TROO

YTEN

Shares of  Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.

Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics Inc

Health Care

Press Releases

General

Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)

Earnings

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting

Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences

Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Immunome

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Kura Oncology

LENZ Therapeutics

MeiraGTx Hldgs

Opthea Limited - American Depositary Shares

Opthea

Organogenesis Hldgs

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Relay Therapeutics

Sana Biotechnology

Sionna Therapeutics

Tyra Biosciences

Valneva

Verve Therapeutics

HC Wainwright & Co.

Oppenheimer

Raymond James

Wedbush

Baird

Comments

Dianthus Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga